Pimavanserin for treating neurodegenerative diseases
WO2021016369A1
Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
WO2020092618A1
Methods of treating depression, anxiety and sexual dysfunction using the compound primavanserin
WO2019177973A1
Methods for assessing suicidality
EP3675827A1
Formulations of pimavanserin
WO2019040106A2
Compounds, salts thereof and their use in the treatment of diseases
WO2019040104A2
Compounds, salts thereof and their use for the treatment of diseases
WO2019040105A2
Compounds, salts thereof and their use in the treatment of diseases
CN111132976A
Compounds, salts thereof and methods for treating diseases
US2020061045A1
Pimavanserin for treating impulse control disorder
EP3558311A1
Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2017172757A1
5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
US2019117636A1
5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
WO2017165635A1
Combination of pimavanserin and cytochrome p450 modulators
US2019047955A1
Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C
WO2015059632A1
Treatment of a neurodegenerative disease or disorder
WO2014125121A1
Compounds and compositions for treating neurodegenerative diseases
WO2014085362A1
Methods for the treatment of parkinson's disease psychosis using pimavanserin
EP2556827A1
Treatment of neurodegenerative diseases
EP2554532A1
Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta
